- Home
- NXP vs VALN Comparison
NXP vs VALN Comparison
Compare NXP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXP | VALN |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.2M | 820.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NXP | VALN |
|---|---|---|
| Price | $14.31 | $8.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 70.0K | 20.4K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | ★ $211,089,992.00 |
| Revenue This Year | N/A | $5.08 |
| Revenue Next Year | N/A | $12.53 |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $12.91 | $3.62 |
| 52 Week High | $14.89 | $12.25 |
Technical Indicators
Market Signals| Indicator | NXP | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 44.50 |
| Support Level | $14.23 | $8.69 |
| Resistance Level | $14.38 | $9.10 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.93 | 14.15 |
Price Performance
Historical ComparisonAbout NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.